Cargando…

Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects

This cross-sectional clinic-based study assessed and compared lipid profile, presence of metabolic syndrome (MetS), and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and normal glucose tolerance (NGT). INTRODUCTION: Type 2 diabetes (T2D) and IGT patients have increased dyslipid...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanyal, Debmalaya, Ghosh, Sujoy, Mukherjee, Pradip, Mukherjee, Satinath, Chowdhury, Subhankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603104/
https://www.ncbi.nlm.nih.gov/pubmed/23565456
http://dx.doi.org/10.4103/2230-8210.104121
_version_ 1782263634156584960
author Sanyal, Debmalaya
Ghosh, Sujoy
Mukherjee, Pradip
Mukherjee, Satinath
Chowdhury, Subhankar
author_facet Sanyal, Debmalaya
Ghosh, Sujoy
Mukherjee, Pradip
Mukherjee, Satinath
Chowdhury, Subhankar
author_sort Sanyal, Debmalaya
collection PubMed
description This cross-sectional clinic-based study assessed and compared lipid profile, presence of metabolic syndrome (MetS), and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and normal glucose tolerance (NGT). INTRODUCTION: Type 2 diabetes (T2D) and IGT patients have increased dyslipidemia, MetS, and alterations in liver enzymes. AIMS AND OBJECTIVES: To assess and compare lipid profile, presence of MetS, and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and NGT. MATERIALS AND METHODS: This cross-sectional clinic-based study examined 152 IGT and 158 recently detected T2D subjects aged between 30 and 69 years, never treated with any anti-hyperglycemic, anti-hypertensive, and lipid lowering drugs. One hundred and sixty age- and gender-matched controls with NGT were also selected. Anthropometry, lipid profile, dyslipidemia (ADA criteria), presence of MetS (NCEP, IDF), liver enzymes, insulin resistance (HOMA-IR and QUICKI), and β-cell function (HOMA β) were analyzed in all subjects. RESULTS: T2D and IGT subjects had significantly higher BMI, waist circumference, blood pressure (BP), HOMA-IR, QUICKI, fasting insulin, HOMA-β, MetS, triglyceride, LDL-C, SGPT, GGT, and lower HDL-C compared to NGT (control). High LDL-C (>100 mg/dl) was the commonest dyslipidemia followed by low HDL-C and hypertriglyceridemia in IGT and T2D. We found no significant differences in BMI, waist circumference, insulin resistance, total/LDL-C/HDL-C, and presence of MetS between T2D and IGT subjects. Diabetics exhibited significantly higher BP, triglyceride, SGPT, GGT, lower fasting insulin, and HOMA-β-cell function compared to IGT. CONCLUSIONS: IGT and recent onset T2D individuals had similar increased cardiovascular risk markers, liver enzymes, and prevalence of MetS. High LDL-C was the commonest dyslipidemia in IGT and T2D. T2D subjects had higher triglyceride, BP, SGPT, GGT compared to IGT.
format Online
Article
Text
id pubmed-3603104
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36031042013-04-05 Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects Sanyal, Debmalaya Ghosh, Sujoy Mukherjee, Pradip Mukherjee, Satinath Chowdhury, Subhankar Indian J Endocrinol Metab Brief Communication This cross-sectional clinic-based study assessed and compared lipid profile, presence of metabolic syndrome (MetS), and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and normal glucose tolerance (NGT). INTRODUCTION: Type 2 diabetes (T2D) and IGT patients have increased dyslipidemia, MetS, and alterations in liver enzymes. AIMS AND OBJECTIVES: To assess and compare lipid profile, presence of MetS, and liver enzymes in subjects with IGT, new onset treatment naïve T2DM, and NGT. MATERIALS AND METHODS: This cross-sectional clinic-based study examined 152 IGT and 158 recently detected T2D subjects aged between 30 and 69 years, never treated with any anti-hyperglycemic, anti-hypertensive, and lipid lowering drugs. One hundred and sixty age- and gender-matched controls with NGT were also selected. Anthropometry, lipid profile, dyslipidemia (ADA criteria), presence of MetS (NCEP, IDF), liver enzymes, insulin resistance (HOMA-IR and QUICKI), and β-cell function (HOMA β) were analyzed in all subjects. RESULTS: T2D and IGT subjects had significantly higher BMI, waist circumference, blood pressure (BP), HOMA-IR, QUICKI, fasting insulin, HOMA-β, MetS, triglyceride, LDL-C, SGPT, GGT, and lower HDL-C compared to NGT (control). High LDL-C (>100 mg/dl) was the commonest dyslipidemia followed by low HDL-C and hypertriglyceridemia in IGT and T2D. We found no significant differences in BMI, waist circumference, insulin resistance, total/LDL-C/HDL-C, and presence of MetS between T2D and IGT subjects. Diabetics exhibited significantly higher BP, triglyceride, SGPT, GGT, lower fasting insulin, and HOMA-β-cell function compared to IGT. CONCLUSIONS: IGT and recent onset T2D individuals had similar increased cardiovascular risk markers, liver enzymes, and prevalence of MetS. High LDL-C was the commonest dyslipidemia in IGT and T2D. T2D subjects had higher triglyceride, BP, SGPT, GGT compared to IGT. Medknow Publications & Media Pvt Ltd 2012-12 /pmc/articles/PMC3603104/ /pubmed/23565456 http://dx.doi.org/10.4103/2230-8210.104121 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Sanyal, Debmalaya
Ghosh, Sujoy
Mukherjee, Pradip
Mukherjee, Satinath
Chowdhury, Subhankar
Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects
title Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects
title_full Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects
title_fullStr Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects
title_full_unstemmed Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects
title_short Dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes Indian subjects
title_sort dyslipidemia, metabolic syndrome, and liver enzymes in impaired glucose tolerance and new onset untreated, type 2 diabetes indian subjects
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603104/
https://www.ncbi.nlm.nih.gov/pubmed/23565456
http://dx.doi.org/10.4103/2230-8210.104121
work_keys_str_mv AT sanyaldebmalaya dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects
AT ghoshsujoy dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects
AT mukherjeepradip dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects
AT mukherjeesatinath dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects
AT chowdhurysubhankar dyslipidemiametabolicsyndromeandliverenzymesinimpairedglucosetoleranceandnewonsetuntreatedtype2diabetesindiansubjects